Health Discovery signs agreement with Patent Profit International

Under the agreement, Patent Profit International (PPI) will market Health Discovery’s (HDC) patent portfolio, which includes exclusive rights to support vector machine techniques and applications that reach far beyond biomarker discovery and the healthcare field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

As a requirement of any sale of the patent estate, HDC expects to retain a royalty-free, worldwide, exclusive license, with the right to grant sublicenses, in the entire field of healthcare.

This strategic initiative is expected to allow HDC to potentially generate significant revenue from its patent estate covering the field of support vector machine technology in non-medical applications while continuing uninterrupted its wide-ranging research, development, licensing and commercialization activities in broad-ranging diagnostic and prognostic areas such as prostate cancer, ovarian cancer, breast cancer, endometrial cancer, colon cancer, leukemia and other healthcare arenas.

According to HDC, this is a strategy designed to transform the company’s underutilized patents into working financial assets to increase shareholder value.